Kymera Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Helps you understand if the company is making money or spending it on research.
Shows the company's revenue, expenses, and losses during the second quarter of 2026.
Leadership changes can affect company strategy and investor confidence in management.
Early completion suggests the drug candidate is progressing faster, potentially reaching patients sooner.
Shareholders voted on key company decisions like board directors and executive pay.
Key leadership departures can signal management changes or strategic shifts at the company.
Shows first quarter performance including research spending and cash position.
Stocky reads Kymera Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Kymera Therapeutics, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Quarterly financial results for period ending June 30, 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.